Amplia Therapeutics (Amplia Therapeutics) Interest Expense : $-0.06 Mil (TTM As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Amplia Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Amplia Therapeutics's interest expense for the six months ended in Sep. 2023 was $ -0.03 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.06 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Amplia Therapeutics's Operating Income for the six months ended in Sep. 2023 was $ -2.32 Mil. Amplia Therapeutics's Interest Expense for the six months ended in Sep. 2023 was $ -0.03 Mil. Amplia Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Amplia Therapeutics Interest Expense Historical Data

The historical data trend for Amplia Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amplia Therapeutics Interest Expense Chart

Amplia Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Interest Expense

Get a 7-Day Free Trial

-0.04

Amplia Therapeutics Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Interest Expense	Get a 7-Day Free Trial															-	-	-0.01	-0.03	-0.03

Amplia Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.06 Mil.

Amplia Therapeutics (OTCPK:INNMF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Amplia Therapeutics's Interest Expense for the six months ended in Sep. 2023 was $-0.03 Mil. Its Operating Income for the six months ended in Sep. 2023 was $-2.32 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Sep. 2023 was $0.04 Mil.

Amplia Therapeutics's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

Amplia Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Amplia Therapeutics (Amplia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (OTCPK:INNMF) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

ATX:Australia

Address

350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000

Website

https://www.ampliatx.com

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics (Amplia Therapeutics) Headlines

From GuruFocus

FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US

By PRNewswire • 01-18-2024

AACR OVARIAN CANCER CONFERENCE PRESENTATION

By PRNewswire • 10-09-2023

AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer

By PRNewswire PRNewswire • 05-29-2023